Oxford Vaccine Group
University of Oxford
Centre for Clinical Vaccinology and Tropical Medicine,
Churchill Hospital, Headington, Oxford OX3 7LE
Telephone: 01865 611400 info@ovg.ox.ac.uk www.ovg.ox.ac.uk

Plague Lay Summary of results:

The plague vaccine ChAdOx1 Plague was tested in healthy adult volunteers, and was tested as either a single dose, or two doses – with the second dose given at either eight weeks or six months after the first.

The trial results showed that ChAdOx1 Plague vaccine causes expected common vaccine side effects such as a sore arm at the vaccination site, and mild to moderate 'flu-like symptoms, which usually last fewer than three days after a dose is received. There were no unexpected or severe symptoms after vaccination found among the study volunteers. The blood tests showed that the immune system responded to the vaccine producing antibodies to the plague proteins that are coded for in the ChAdOx1 Plague vaccine. Two doses produced higher antibody responses than one by vaccine dose, with a suggestion that this may be better when the second dose is given later (at six months after the first) rather than earlier (at two months after the first). Responses were seen against both plague proteins with those against LcrV plague protein higher than the F1 plague protein. There was variability in responses between individuals. In summary, the vaccine was shown to be well tolerated, with expected side-effects, and there was evidence that it stimulates immune responses against important plague proteins.